论文部分内容阅读
目的观察舒利迭联合噻托溴铵粉吸入剂对比舒利迭联合沐舒坦治疗慢性阻塞性肺疾病(COPD)的临床疗效,探讨其治疗COPD的安全性及有效性,为临床治疗方法提供参考依据。方法选取该院就诊的210例COPD患者随机分为舒利迭组、舒利迭联合噻托溴铵粉吸入剂治疗组及舒利迭联合沐舒坦治疗组,每组各70例。根据治疗后PO2、PCO2及肺功能、体征评分等为指标对患者恢复程度进行评估。结果治疗后,三组治疗结果均有显著改善,其中舒利迭组在用药3个月内效果显著,舒利迭联合沐舒坦在用药3~6个月内效果显著,舒利迭联合噻托溴铵粉吸入剂在3~12个月效果显著。结论舒利迭联合噻托溴铵粉吸入剂在治疗COPD的远期临床疗效好,舒利迭联合沐舒坦在治疗COPD过程中展现的短期疗效显著,此结果可为后期临床中用药提供依据。
Objective To observe the clinical efficacy of seretide combined with tiotropium bromide powder inhaler in the treatment of chronic obstructive pulmonary disease (COPD) and compare the safety and efficacy of seretide combined with ambroxol in the treatment of chronic obstructive pulmonary disease (COPD). in accordance with. Methods Two hundred and seventy COPD patients were randomly divided into seretide group, seretide combined with tiotropium bromide inhaler and seretide combined with mucosolvan group, 70 cases in each group. According to the post-treatment PO2, PCO2 and pulmonary function, physical signs and other indicators as the index to evaluate the degree of patient recovery. Results After treatment, the results of the three groups were significantly improved, among which the effect of salmeterol was significant within 3 months, the effect of salvianolate and ambroxol was significant within 3-6 months after treatment, Bromine powder inhaler in 3 to 12 months significant effect. Conclusion The combination of seretide combined with tiotropium bromide powder inhaler has good long-term clinical efficacy in the treatment of COPD. The short-term curative effect of seretide combined with ambroxol in the treatment of COPD is significant. This result can provide basis for the clinical use in the later stage.